Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-16, Stock:JNJ, The news for the past five days is as follows:
2018-02-09: NEWS1: 7 Blue-Chip Stocks to Buy Amid Record Selloff.NEWS2: 7 Blue-Chip Stocks to Buy Amid Record Selloff.NEWS3: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson.NEWS4: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS5: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS6: FDA Okays J&J's Prostate Cancer Drug in First-Line Setting.NEWS7: FDA Okays J&J's Prostate Cancer Drug in First-Line Setting.NEWS8: Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study.NEWS9: Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study.NEWS10: FDA Okays J&J&apos;s Prostate Cancer Drug in First-Line Setting.NEWS11: Rosen Law Firm Files Securities Class Action Lawsuit Against Johnson & Johnson.NEWS12: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS13: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018.NEWS14: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline: April 9, 2018.NEWS15: What Drove Pfizer’s 4Q17 Growth?.NEWS16: Amgen’s Neulasta and Enbrel in 4Q17 and 2017.NEWS17: 3 Dividend Stocks Perfect for Retirement.NEWS18: 3 Dividend Stocks Perfect for Retirement.NEWS19: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS20: How Did Pfizer’s Geographical Regions Perform in 4Q17?.NEWS21: 3 Dividend Stocks Perfect for Retirement.NEWS22: JNJ INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Johnson & Johnson Investors.NEWS23: FDA Nod For JNJ, CORI Awaits Results In Q2, MDGL's HeFH Data Fails To Impress.NEWS24: FDA Nod For JNJ, CORI Awaits Results In Q2, MDGL's HeFH Data Fails To Impress.
2018-02-12: NEWS1: Bristol-Myers Squibb’s 4Q17 Earnings Performance.NEWS2: Is AbbVie or Vertex Pharmaceuticals the Better Buy Now?.NEWS3: INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson -- JNJ.NEWS4: Health Care Select Sector SPDR Fund Experiences Big Outflow.NEWS5: Health Care Select Sector SPDR Fund Experiences Big Outflow.NEWS6: What Analysts Recommend for Pfizer after 4Q17.NEWS7: New drug promises to kill flu virus in a day.NEWS8: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS9: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS10: What’s Pfizer’s Valuation after 4Q17 Earnings?.NEWS11: Amgen’s Nephrology Drugs: Aranesp, Epogen, Sensipar in 4Q17.NEWS12: [$$] The Tax Law Is About to Make Analyzing Earnings Trickier.NEWS13: [$$] Experimental Drug Promises to Kill the Flu Virus in a Day.
2018-02-13: NEWS1: Where Pfizer Stands in Biosimilars after 2017.NEWS2: Will Medtronic See Lower Sales Again in 3Q18?.NEWS3: Opioid Litigants Get Boost From Senate Report.NEWS4: How Pfizer Performed Overall in 4Q17 and 2017.NEWS5: JNJ LOSS NOTICE: Rosen Law Firm Reminds Johnson & Johnson Investors of Important Deadline in First Filed Case.NEWS6: JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson.NEWS7: Eliquis: Bristol-Myers Squibb’s Cardiovascular Blockbuster in 4Q17.NEWS8: SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Johnson & Johnson (JNJ) & Lead Plaintiff Deadline - April 9, 2018.NEWS9: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS10: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS11: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018.NEWS12: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018.NEWS13: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS14: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS15: What to Expect from Pfizer’s Xtandi in 2018.NEWS16: Integration Progress of BDX’s Recent Acquisitions and Synergies.NEWS17: [$$] The Tax Law Is About to Make Analyzing Earnings Trickier.NEWS18: Opioid makers gave $10M to advocacy groups amid epidemic.NEWS19: Opioid makers gave $10M to advocacy groups amid epidemic.NEWS20: Opioid makers paid millions to advocacy groups -U.S. Senate report.NEWS21: INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Johnson & Johnson.NEWS22: Opioid makers paid millions to advocacy groups -U.S. Senate report.NEWS23: SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Johnson & Johnson (NYSE: JNJ) To Contact Brower Piven Before The Lead Plaintiff Deadline.
2018-02-14: NEWS1: FDA approves J&J prostate cancer treatment.NEWS2: ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Johnson & Johnson.NEWS3: Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Johnson & Johnson (JNJ).NEWS4: JNJ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson.NEWS5: What To Expect From Roche In 2018.NEWS6: What To Expect From Roche In 2018.NEWS7: Cory Booker joins Kirsten Gillibrand and other Senate Democrats in rejecting corporate PAC donations.NEWS8: Cory Booker joins Kirsten Gillibrand and other Senate Democrats in rejecting corporate PAC donations.NEWS9: Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017.NEWS10: Bristol-Myers Squibb’s Valuation after Its 4Q17 Earnings.NEWS11: The Decline In Johnson & Johnson Could Be Close to Being Over.NEWS12: Behind Pfizer’s Internal Medicines in 2017.NEWS13: Bristol-Myers Squibb’s Orencia and Other Brands in 4Q17.
2018-02-15: NEWS1: Glancy Prongay & Murray LLP Continues Investigation on Behalf of Johnson & Johnson Investors (JNJ).NEWS2: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS3: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One's a Marijuana Stock).NEWS4: A Snapshot Of Abbott Labs' Business.NEWS5: A Snapshot Of Abbott Labs' Business.NEWS6: The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Johnson & Johnson.NEWS7: 6 Healthcare Stocks We Think Deserve Gold Medals (Hint: One&apos;s a Marijuana Stock).NEWS8: J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment.NEWS9: J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment.NEWS10: J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment.NEWS11: How Pfizer’s Peri-LOE Products Performed in 2017.NEWS12: Today’s Research Reports on Trending Tickers: Johnson & Johnson and Merck & Company.NEWS13: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS14: Where Pfizer’s Xeljanz Is Positioned for 2018.NEWS15: How Analysts View Bristol-Myers Squibb after Its 4Q17 Earnings.NEWS16: Why Defensive ETFs Fail in the Market Downturn?.NEWS17: Why Defensive ETFs Fail in the Market Downturn?.

Answer: Rise